Traduction de «information on the packaging » (Anglais → Français) :

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

ensure the integrity of letters and packages | prevent mail from being damaged | ensure the condition of letters and packages | ensure the integrity of mail

Convention concerning the Marking of the Weight on Heavy Packages Transported by Vessels | Marking of Weight (Packages Transported by Vessels) Convention, 1929

package insert | package leaflet | patient information leaflet | patient package insert | PIL [Abbr.] | PL [Abbr.]

apply shipment packing requirements | receive information on shipment packaging requirements | interpret shipment packaging information | receive shipment packaging information

Definition: This category includes only mental disorders associated with the puerperium (commencing within six weeks of delivery) that do not meet the criteria for disorders classified elsewhere in this chapter, either because insufficient information is available, or because it is considered that special additional clinical features are present that make their classification elsewhere inappropriate.

Abuse and Neglect of Older Adults: Information Package for People in the Workplace

European Association for the Flexible Packaging Industry | European Flexible Packaging Federation | EFPF [Abbr.]

Packaging Audits and Packaging Reductions Workplans : Guidelines to help industry meet the goals of the National Packaging Protocol

inform on the effects of childbirth on sexuality | provide advice on the effects of childbirth on sexuality | provide information on the effects of childbirth on sexuality | provide information on the impact of childbirth on sexuality

Press release - Security Union: Commission proposes a European Travel Information and Authorisation System Proposal for a Regulation establishing a European Travel Information and Authorisation System Annex Remarks by Vice-President Dombrovskis at the European Commission press conference on the Autumn Economic Package Remarks by Commissioner Thyssen on the 2017 Joint Employment Report at the European Commission press conference on the Autumn Economic Package Feasibility study on a European Travel Information and Authorisation System ...[+++] MEMO: European Travel Information and Authorisation System: Questions Answers FACTSHEET: A European Travel Information and Authorisation System

1. Member States shall ensure that, before the traveller is bound by any package travel contract or any corresponding offer, the organiser and, where the package is sold through a retailer, also the retailer shall provide the traveller with the standard information by means of the relevant form as set out in Part A or Part B of Annex I, and, where applicable to the package, with the following information:

21 (1) Where a consumer textile article is sold to the consumer in a wrapper, package or container, the information that is required by section 11 to be shown in a label shall be shown on such wrapper, package or container and in the prescribed manner unless the disclosure label is applied and the article wrapped, packaged or contained in such a manner that the information in the label is clearly visible to the prospective purchaser when the article is in the wrapper, package or container.

With reference to the side effects experienced by those taking the anti-malarial drug mefloquine (Lariam): (a) provide a detailed update on the clinical study of mefloquine (Lariam) announced by the Department of National Defence in 1997, including trial design, subject inclusion/exclusion criteria, numbers of study subjects recruited to date and participating centres; (b) have reviews been undertaken of the side effects experienced by the Australian, British and Dutch forces, if so what were the results and recommendations, and what steps have been undertaken to implement these recommendations; (c) with regard to the mefloquine (Lariam) used for the prophylaxis of Canadian troops deployed to Somalia, what was the nature of the Department ...[+++] of Health's Health Protection Branch investigations in October 1997 into the failure of the manufacturer to properly supervise and ensure compliance with the Lariam safety monitoring study and the failure of the Department of National Defence to comply with its obligations under the safety monitoring study; (d) with regard to the mefloquine (Lariam) used for the prophylaxis of Canadian troops deployed to Somalia, what was the outcome of the Department of Health's Health Protection Branch investigations in October 1997 into the failure of the manufacturer to properly supervise and ensure compliance with the Lariam safety monitoring study and the failure of the Department of National Defence to comply with its obligations under the safety monitoring study; (e) what is the date of the insert in the mefloquine (Lariam) package used in Canada today; (f) what is the date of the product monograph for mefloquine (Lariam) used in Canada today; (g) have reviews been undertaken of the insert in the mefloquine (Lariam) package and the prescribing information used in Australia, if so what were the results and recommendations of the reviews, and what steps have been taken to implement the recommendations; (h) have reviews been undertaken ...